timothy sykes logo
ImmunityBio Secures Major Milestone With ANKTIVA in Asia-Pacific Expansion Thumbnail
ADD US ONG Google News

ImmunityBio Secures Major Milestone With ANKTIVA in Asia-Pacific Expansion

JACK KELLOGG•UPDATED MAR. 31, 2026, 11:32 AM ET
Reviewed by Tim Sykes Fact-checked by Ellis Hobbs

ImmunityBio Inc.’s stock surges 9.08% after promising FDA designation boosts investor confidence in future growth.

Candlestick Chart

Live Update At 11:32:18 EDT: On Tuesday, March 31, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 9.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio recently experienced fluctuating stock performance with drops from highs around March 24, marked by volatility from various news intermittences. The company’s financials reveal some challenges but promise potential. With a gross margin sitting robustly at 99.3%, it’s evident the firm can handle its operational costs effectively, despite negative profitability ratios like an EBIT margin of -278.4% and a pretax profit margin of -1630%.

Over recent weeks, the stock showed resilience, closing at $7.265 from a major dip at $8.47 on March 20. Market performance improvement is linked to strategic endeavors like the ANKTIVA global rollout. Despite a significant market cap at $5.27B, operational cash flow challenges such as an approximate $7.16M free cash flow demand scrutiny. Trading actions suggest careful navigation owing to a high price-to-sales ratio of 85.31, indicating overvaluation may be a risk.

Strategic Moves Spark Optimism

Recent news highlights ImmunityBio’s strategic expansion and breakthroughs. One of the biggest was the ANKTIVA addition to 2026 NCCN Guidelines, enhancing its application potential and increasing payer support. This moves ImmunityBio a step closer to greater clinical adoption pending an FDA review. Simultaneously, the Phase 2b QUILT-2.005 trial’s full enrollment marks a solid regulatory filing trajectory set for late 2026.

In an ambitious Asian market foray, Macau’s regulatory nod signifies ImmunityBio’s entrance into Asia-Pacific, fortifying its global distribution footprint. Leverage on previous FDA and EMA approvals, the firm bridges its US and EU successes towards wider Asian adoption. Manufacturing success in large-scale NK (M-ceNK) cell production, validated with safety feasibility trials, further promises capability for rapid population-scale interventions in cancer treatment.

The analysts’ outlook reflects growing confidence. BTIG’s confirmed Buy rating resonates through a backdrop of remarkable ANKTIVA revenue acceleration, which climbed 700% year-over-year to $113M in 2025, projected to hit $195M in 2026.

More Breaking News

Market Reactions and Implications

The recent flurry of developments places ImmunityBio at an interesting juncture. It’s clear the activities will shape its competitive positioning and market perception. Traders respond, toggling their stakes guided by risk considerations parallel to expansive strategies boosting ANKTIVA’s footprint. Observably, strategic product placements in pivotal guidelines tend to bump financial earnings expectations considering payer support enhancement.

With manufacturing affirmed, ImmunityBio portrays readiness for operational demands that come with scientific advancements. Its efficient production lines underscore an adaptive commercial strategy preparing for scaling demands without compromising output quality. Such achievements embolden traders’ faith while stirring market recalibrations reacting to comprehensive innovation narratives.

As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” This caution resonates with the trading community navigating ImmunityBio’s unfolding strategies. Expectations remain cautiously optimistic amid tangible fiscal challenges juxtaposed with spirited regulatory and market engagements for ANKTIVA. Anticipated fiscal health rejuvenates trader interest held steady by strategic uptake and shrewd expert prognostications. Elements projecting successful ventures underpin evaluations, recommending lukewarm exuberance peppered with diligent risk assessments.

In the subsequent response, factors accompanying ANKTIVA’s global trajectory are integral. Traders’ anticipative sentiments report enthusiasm, layered with speculative caution informed by press releases, aligning stock positions reflecting diversified opinion spectra.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”